PA
PA8.F Paion AG
- Market cap
- EUR 46.2M
- P/E
- -
- P/B
- 2.84x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2023.
Is PA8.F undervalued?
Graham numberThe Graham number of Paion AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Paion AG fundamental analysis
No fundamental analysis for Paion AG yet.
Paion AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the trea…
Full company profilePaion AG financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Paion AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.23M | 3.46M | 71.6K | 4.26M | 5.81M | 2.77M | 8.00M | 19.7M | 7.13M | 33.2M | 18.1M |
| Gross Profit | 4.23M | 3.45M | 60.7K | 4.26M | 5.81M | 2.77M | 8.00M | 19.7M | 4.05M | 31.3M | 6.02M |
| Operating Income | -3.16M | -12.0M | -35.0M | -25.1M | -15.9M | -12.5M | -9.33M | 1.58M | -22.0M | 1.51M | -14.4M |
| EBITDA | - | - | - | - | -15.5M | -12.2M | -9.21M | 1.94M | -18.8M | 4.31M | - |
| Net Income | -2.21M | -9.10M | -28.2M | -20.1M | -12.1M | -9.94M | -7.02M | 2.22M | -21.8M | -579K | -17.9M |
| EPS | - | - | - | - | -0.19 | -0.15 | -0.11 | 0.03 | -0.31 | -0.08 | -2.51 |
| Balance Sheet | |||||||||||
| Total Assets | 18.0M | 66.5M | 43.5M | 38.0M | 31.9M | 24.3M | 24.9M | 28.1M | 36.8M | 38.2M | 32.2M |
| Total Liabilities | 4.69M | 3.94M | 7.91M | 13.0M | 6.66M | 3.50M | 10.2M | 6.86M | 29.8M | 31.6M | 35.3M |
| Shareholders' Equity | 13.3M | 62.6M | 35.6M | 24.9M | 25.2M | 20.8M | 14.7M | 21.3M | 7.00M | 6.62M | -3.07M |
| Cash & Short-term Investments | 13.3M | 58.9M | 32.7M | 30.1M | 24.8M | 17.2M | 18.8M | 19.7M | 6.44M | 10.6M | 4.65M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.75M | -12.0M | -26.3M | -11.6M | -17.7M | -12.8M | -2.85M | 906K | -21.2M | 5.94M | - |
| Capital Expenditure | 5.24K | 26.5K | 33.5K | 199K | 25.0K | 13.1K | 15.3K | 13.7K | 19.2M | 1.59M | 0.00 |
| Free Cash Flow | - | - | - | - | -17.7M | -12.8M | -2.86M | 892K | -40.4M | 4.36M | - |
| Ratios | |||||||||||
| ROE | -16.6% | -14.5% | -79.3% | -80.7% | -47.9% | -47.7% | -47.6% | 10.4% | -311.3% | -8.8% | - |
| ROA | -12.3% | -13.7% | -64.9% | -53.0% | -37.9% | -40.9% | -28.2% | 7.9% | -59.2% | -1.5% | -55.4% |
| Net Profit Margin | -52.3% | -263.5% | -39,395.0% | -472.0% | -208.1% | -359.4% | -87.7% | 11.3% | -305.6% | -1.7% | -98.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Paion AG dividends
Paion AG has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Apr 12, 2023.
Who owns Paion AG
- Insiders 8.00%
- Institutions 3.74%
- Public & others 88.26%
- Shares outstanding 7.13M
- Free float 6.48M
Paion AG company profile
- Company name
- Paion AG
- Ticker
- PA8.F
- ISIN
- DE000A0B65S3
- Exchange
- Frankfurt Exchange
- Sector
- -
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 70
- Fiscal year end
- December
- Address
- Heussstrasse 25, Aachen, Germany, 52078
- Phone
- 49 2414 4530
- Website
- paion.com
About Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Paion AG management
5- Dr. James Neil Phillips ChB, M.B.A., M.D., MB, MBACEO & Chairman of Management Board · born 1962
- Mr. Sebastian WernerMember of Management Board & CFO
- Ralf PennerVP of Investor Relations & PR
- Dr. Shaw SorooshianSr. VP of Medical Affairs · born 1964
- Dr. Thomas StoehrSr. VP of Devel.